Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab - Genentech

Drug Profile

Atezolizumab - Genentech

Alternative Names: Anti-PDL-1-Genentech/Roche; MPDL-3280A; RG-7446; RO-5541267; TECENTRIQ

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer Amgen; ARCAGY/GINECO Group; BioLineRx; Chugai Pharmaceutical; Clovis Oncology; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Exelixis; Fondazione Michelangelo; GEICO (Spanish Ovarian Cancer Research Group); Genentech; GERCOR; German Breast Group; Gradalis; H. Lee Moffitt Cancer Center and Research Institute; Immune Design; Incyte Corporation; Johns Hopkins University; Kaiser Permanente; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Center (Korea); National Cancer Institute (USA); Netherlands Cancer Institute; NSABP Foundation; Roche; Sanofi; Seattle Genetics; University Hospital Southampton NHS Foundation Trust; University Medical Center Groningen; University of California; University of California at San Francisco; University of Oklahoma; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Small cell lung cancer; Urogenital cancer
  • Phase III Bladder cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Phase II Anal cancer; Brain metastases; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Gynaecological cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Oesophageal cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute myeloid leukaemia; Follicular lymphoma; Glioblastoma; Pancreatic cancer
  • Phase I Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
  • Discontinued Hodgkin's disease; Myelodysplastic syndromes; Prostate cancer

Most Recent Events

  • 06 Dec 2019 Launched for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan (IV)
  • 04 Dec 2019 US FDA approves atezolizumab for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 26 Nov 2019 Phase-III clinical trials in Liver cancer (Adjuvant therapy, Combination therapy, Late-stage disease, Second-line therapy or greater, Recurrent) in USA, Australia, Hong Kong, South Korea, Spain (IV, Infusion) (NCT04102098)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top